Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines.
The monoclonal antibodies (MAbs) HD37 and RFB4 bind to receptors on precursor B acute lymphoblastic leukemia (ALL) cells. These MAbs were tested alone and in combination with chemotherapy for their anti-leukemic activity. HD37 and not RFB4 increased the in vitro cytotoxicity of daunorubicin (DNR) and vincristine (VCR) in three Pre-B ALL cell lines. HD37 alone induced apoptosis in 30% of the cells versus 2% for RFB4. The treatment of SCID/ALL mice with either chemotherapy agent minimally prolonged their mean survival time (MST) versus controls but HD37 or RFB4 plus VCR significantly extended the MST. Forty percent of the mice treated with HD37 plus VCR survived. In conclusion, chemotherapy was made more effective when combined with HD37, and less so with RFB4.
Stanciu-Herrera
C
C
Department of Microbiology and Immunology, Temple University Medical School, Philadelphia, PA 19140, USA.
Morgan
C
C
Herrera
L
L
D000208:Acute Disease; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018941:Antigens, CD19 / Q000276:immunology*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D003630:Daunorubicin / Q000627:therapeutic use; D004357:Drug Synergism; D006801:Humans; D008297:Male; D051379:Mice; D016513:Mice, SCID; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology*; D015996:Survival Rate; D014407:Tumor Cells, Cultured; D014750:Vincristine / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D018941:Antigens, CD19; D000972:Antineoplastic Agents, Phytogenic; D051918:Sialic Acid Binding Ig-like Lectin 2; D014750:Vincristine; D003630:Daunorubicin
Arch Pathol Lab Med. 2003 Jan;127(1):42-8
12521365
Am J Clin Pathol. 2002 Mar;117(3):380-9
11888077
J Clin Oncol. 2003 Jul 15;21(14):2787-99
12860957
Anticancer Drugs. 2003 Oct;14(9):669-82
14551500
Cytometry B Clin Cytom. 2003 Nov;56(1):30-42
14582135
Clin Cancer Res. 2004 Feb 15;10(4):1274-81
14977825
Exp Cell Res. 2004 Aug 15;298(2):560-73
15265702
J Immunol. 1987 May 1;138(9):2793-9
2437199
Leuk Res. 1988;12(2):135-41
3282129
Blood. 1988 Jul;72(1):299-307
3291983
Cancer Res. 1989 Sep 1;49(17):4906-12
2667754
J Immunol. 1991 Dec 1;147(11):3663-71
1719083
Crit Rev Oncol Hematol. 1991 Dec;11(4):267-97
1777090
Blood. 1992 Nov 1;80(9):2315-20
1384801
Blood. 1993 Nov 1;82(9):2624-33
8219217
Blood. 1994 Mar 1;83(5):1329-36
7509655
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4048-52
7513431
Curr Opin Oncol. 1994 Jan;6(1):14-22
8204688
J Immunol. 1995 Apr 1;154(7):3096-104
7534787
Blood. 1995 Jun 15;85(12):3457-65
7780133
Leuk Lymphoma. 1995 Aug;18(5-6):385-97
8528044
Curr Biol. 1997 Feb 1;7(2):133-43
9016707
Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7509-14
9207122
Leuk Res. 1998 Jul;22(7):567-79
9680106
J Immunol. 1998 Sep 15;161(6):3176-85
9743386
Exp Hematol. 2005 Feb;33(2):199-211
15676214
J Clin Oncol. 2005 Feb 1;23(4):694-704
15681517
J Clin Oncol. 2005 Jun 1;23(16):3676-85
15738535
Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15178-83
16217038
Leukemia. 2003 Feb;17(2):334-8
12592332
Clin Cancer Res. 1999 Dec;5(12):3920-7
10632321
Clin Cancer Res. 2000 Apr;6(4):1302-13
10778955
Immunity. 2000 Jul;13(1):47-57
10933394
Br J Haematol. 2001 Sep;114(4):800-9
11564066
J Biol Chem. 2001 Nov 23;276(47):44315-22
11551923